Apiban to Help Dialysis Fistulas Mature Successfully
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether a blood-thinner medication called apixaban (Apiban) helps arteriovenous fistulas—surgically created connections in the arm for dialysis—develop and work better. If it helps fistulas mature faster and more reliably, it could reduce complications and improve treatment for kidney failure patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have end-stage kidney disease (very low kidney function, eGFR below 15, or already on dialysis) and will need hemodialysis.
- You are having surgery to create a new fistula in your upper arm (wrist or elbow area).
- Your arm veins and arteries are large enough for a fistula (measured by ultrasound before surgery).
- You can follow study instructions and attend follow-up visits.
- You do not have a bleeding disorder or take multiple blood-thinning medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device called the Velocity pAVF System that creates a connection between a vein and artery in your arm for hemodialysis. If you need dialysis now or within the next 6 months, this could be a new option for you.
This study looks at whether blood markers and the condition of your blood vessels before surgery can predict how well a new dialysis access (fistula) will work. It aims to help doctors identify patients who may need extra care to ensure their fistula matures properly.
This trial tests a special wrap placed around a new arm access point for dialysis (called an AV fistula) to see if it helps the access stay healthy and work better. It is for people who need a new AV fistula for kidney dialysis.
This trial tests whether a drug-coated balloon works better than a plain balloon to open up narrowed spots in your dialysis access. If you have a failing AVF with a narrowing that can be treated, this study may help improve your dialysis.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study tests whether adding a low dose of a blood thinner called apixaban (also known as Eliquis) to the standard solution used to keep dialysis catheters open will help prevent them from getting blocked. It could improve the reliability of your dialysis treatments and reduce the need for catheter replacements.
Hear when a new Direct Oral Anticoagulants (DOACs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.